Pancreatic cancer has the worst survival rate of any major cancer. The standard chemotherapy combination of gemcitabine and nab-paclitaxel (Abraxane) only keeps patients alive for an average of nine months. Treatment is difficult because pancreatic tumours are protected by an armour of connective tissue, blood vessels and immune cells, known collectively as the stroma. Read more . . .
A drug that is already used to treat strokes can significantly prolong the survival of mice with pancreatic cancer.